Logo

Generium and Selexis Launch Eculizumab Biosimilar for Paroxysmal Nocturnal Hemoglobinuria (PNH) and Hemolytic Uremic Syndrome (aHUS) in Russia

Share this

Generium and Selexis Launch Eculizumab Biosimilar for Paroxysmal Nocturnal Hemoglobinuria (PNH) and Hemolytic Uremic Syndrome (aHUS) in Russia

Shots:

  • Generium’s biosimilar of Eculizumab is developed using Selexis’ SUREtechnology Platform which is based on Selexis SGE (Selexis Genetic Elements) consist of human DNA based element- controlling the chromatin across mammalian cells
  • Eculizumab is a monoclonal IgG2/4 Ab developed as a fifth biosimilar SUREtechnology Platform involved in reduction of the destruction of red blood cells and need for blood transfusion & improves renal function in patients with PNH & aHUS respectively
  • Currently 115 clinical programs are utilizing the SUREtechnology Platform including 9 P-III programs useful in addressing complicated and intractable diseases by developing complex protein therapies

Ref: Selexis | Image: Twitter

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions